ALPL and hypophosphatasia: The high level of disease burden among registry patients regardless of age of onset, presence of skeletal manifestations, or number of ALPL variants may be important in determining which patients should receive treatment with enzyme replacement therapy, especially given that symptoms of HPP may evolve and accumulate throughout the course of a patient’s life [9].